First-Line Rybrevant Plus Lazcluze Shows Trend Toward Overall Survival in EGFR-Positive NSCLC
First-Line Rybrevant Plus Lazcluze Shows Trend Toward Overall Survival in EGFR-Positive NSCLCIn the first line of treatment, Rybrevant (amivantamab) plus ...